doi:10.1016/j.peptides.2007.04.004
Copyright © 2007 Elsevier Inc. All rights reserved.
Microarray analyses of pituitary adenylate cyclase activating polypeptide (PACAP)-regulated gene targets in sympathetic neurons
References and further reading may be available for this article. To view references and further reading you must
purchase this article.
Karen M. Braasa, Kristin C. Schutza, Jeffrey P. Bondc, Margaret A. Vizzarda, b, Beatrice M. Girarda, b and Victor Maya,
, 
aDepartment of Anatomy and Neurobiology, The University of Vermont College of Medicine, Burlington, VT 05405, United States
bDepartment of Neurology, The University of Vermont College of Medicine, Burlington, VT 05405, United States
cDepartment of Bioinformatics Core Facility, The University of Vermont College of Medicine, Burlington, VT 05405, United States
Received 1 February 2007;
revised 29 March 2007;
accepted 10 April 2007.
Available online 19 April 2007.
Abstract
The high and preferential expression of the PAC1(short)HOP1 receptor in postganglionic sympathetic neurons facilitates microarray studies for mechanisms underlying PACAP-mediate neurotrophic signaling in a physiological context. Replicate primary sympathetic neuronal cultures were treated with 100 nM PACAP27 either acutely (9 h) or chronically (96 h) before RNA extraction and preparation for Affymetrix microarray analysis. Compared to untreated control cultures, acute PACAP treatment modulated significantly the expression of 147 transcripts of diverse functional groups, including peptides, growth factors/cytokines, transcriptional factors, receptors/signaling effectors and cell cycle regulators, that collectively appeared to facilitate neuronal plasticity, differentiation and/or regeneration processes. Some regulated transcripts, for example, were related to BDNF/TrkB, IL-6/Jak2/Socs2 and TGF/follistatin signaling; many transcripts affected bioactive peptide and polyamine biosynthesis. Although chronic PACAP treatments altered the expression of 109 sympathetic transcripts, only 43 transcripts were shared between the acute and chronic treatment data sets. The PACAP-mediated changes in transcript expression were corroborated independently by quantitative PCR measurement. The PACAP-regulated transcripts in sympathetic neurons did not bear strong resemblance to those in PACAP-treated pheochromocytoma cells. However, many PACAP-targeted sympathetic transcripts, especially those related to peptide plasticity and nerve regeneration processes, coincided significantly with genes altered after peripheral nerve injury. The ability for sympathetic PAC1(short)HOP1 receptors to engage multiple downstream signaling cascades appeared to be reflected in the number and diversity of genes targeted in a multifaceted strategy for comprehensive neurotrophic responses.
Keywords: PACAP; PAC1 receptor; Sympathetic; Superior cervical ganglion; Neurotrophic
Fig. 1. Volcano plot demonstrate differential regulation of PACAP-targeted genes. Sympathetic transcripts identified on the Affymetrix U34 microarray to be regulated by 9 h acute (A) or 96 h chronic (B) peptide treatments were represented as correlation between robust multichip average expression index (M, log2 fold change) and p-value (−log10 p) for each of the 8799 genes. Criteria boundaries are shown for each plot. Transcripts upregulated following PACAP treatment are designated by open circles in the upper right quadrants; transcript expression diminished by PACAP are shown in upper left quadrants. Compared to panel A, the decrease in number of gene targets in the upper right quadrant of panel B reflects the transient nature of many induced transcripts after chronic PACAP treatment. The transcript in the extreme upper right of each plot is VIP.
Fig. 2. PCR studies corroborate PACAP-regulated transcript response magnitude and temporal dynamics shown by microarray analyses. Sympathetic cultures were treated with 100 nM PACAP27 and prepared for semi-quantitative (A) and quantitative (B) PCR analyses as described in Section 2. The peptide treatment times corresponded to those submitted for the microarray experiments to facilitate comparisons; the transcripts analyzed were representative of peptide, growth factor and receptor transcripts that demonstrated temporal differences in expression. The expression patterns of select transcripts after PACAP treatment followed those described in the gene chip studies; from quantitative PCR, the magnitude of the responses was frequently underestimated in the array data. Data from the quantitative PCR studies represent fold changes compared to untreated control cultures (n = 3) ± S.E.M.
Table 1.
PCR oligonucleotide primers

Table 2.
PACAP-regulated sympathetic transcripts after acute and chronic treatments

Fold change (fold Δ) in the acute (9 h) and chronic (96 h) transcript sets, and the corresponding p-values represent data compared to untreated control cultures (n = 3); transcripts in italics are downregulated after PACAP treatment. nc, not changed from control cultures.
* Statistical difference between 9 h and 96 h PACAP-treated cultures.
Table 3.
Sympathetic transcripts uniquely regulated by PACAP after chronic treatment

Fold change (fold Δ) for the chronic (96 h) transcript set and the corresponding p-values represent data compared to untreated control cultures (n = 3); transcripts in italics are downregulated after PACAP treatment. nc, not changed from control cultures.
Corresponding author at: Departments of Anatomy & Neurobiology, and Pharmacology, University of Vermont College of Medicine, 149 Beaumont Avenue, Health Science Research Facility, Room 428, Burlington, VT 05405, United States. Tel.: +1 802 656 4579; fax: +1 802 656 8704.